Alexion Pharma (ALXN) Cash Flow Statement

Click line-items for a historical chart and %

Net income	207.11M
Depreciation and amortization	194.58M
Change in fair value of contingent consideration
Share-based compensation expense	104.87M
Deferred taxes	76.15M
Marketable securities premium amortization
Unrealized foreign currency (gain) loss	-4.07M
Unrealized (gain) loss on forward contracts
Loss on disposal of property, plant and equipment
Accounts receivable	-65.22M
Inventories	-39.04M
Prepaid expenses and other assets	-88.13M
Accounts payable and accrued expenses	-6.7M
Deferred revenue	33.38M
Net cash provided by operating activities	411.92M
Purchases of marketable securities
Proceeds from maturity or sale of marketable securities
Purchases of property, plant and equipment	-131.03M
Purchase of technology rights
Payments for acquisition of business, net of cash acquired	0
Increase in restricted cash
Net cash used in investing activities	-336.34M
Payments on capital leases
Excess tax benefit from stock options	479K
Proceeds from revolving credit facility
Payments on revolving credit facility
Net proceeds from the exercise of stock options
Net cash provided by financing activities	-490.35M
Effect of exchange rate changes on cash	2.21M
Net change in cash and cash equivalents	-412.56M
Cash and cash equivalents at beginning of period	1.01B
Cash and cash equivalents at end of period	597.55M

Entities mentioned with ALXN

View All Entities